EpiBiologics closed a $107 million Series B to advance EPI‑326, a bispecific antibody designed to degrade tumor EGFR via targeted lysosomal routing, into first‑in‑human studies. The Bay Area startup, founded by former Genentech leaders, said the financing was led by GV and Johnson & Johnson’s venture arm and will support IND‑enabling work and an initial clinical trial expected in H1 2026. The company positions its EpiTAC degraders as a way to remove disease‑causing surface proteins with tumor specificity to improve safety and enable combinations with existing therapies. Investors cited promising preclinical activity and safety as drivers for the round.